Deep Analytical Insights: The AI-driven analysis extracts a wealth of data on muscle and fat composition, strengthening clinical endpoints for pediatric FSHD trials and potentially expediting regulatory pathways.

"This study will be fundamental in helping us define how the disease progresses in children and whether there are distinct subgroups," said Seth Friedman, PhD, Director of Imaging at Seattle Children's and a PI in the MOVE Peds trial. "From our adult data, we have learned that tracking individual muscles is critical to following the disease over time. This will likely be even more important in kids given they are rapidly growing."


Laying the Groundwork for Pediatric FSHD Drug Development

MOVE Peds will enroll pediatric FSHD patients across eight clinical sites, capturing both early-onset and later-onset pediatric forms of the disease. Using MRI and functional testing optimized for children, it will allow the team to accurately track the natural history of disease progression and create models to estimate treatment effects.

"At Springbok, we are redefining what's possible with muscle MRI imaging, ensuring the process is patient-friendly, rapid and scalable and the analytics are precise, scientifically valid and useful," said Scott Magargee, CEO of Springbok Analytics. "As part of the MOVE Peds study in particular, we are supporting the incredibly important research being conducted by these world-renowned scientists and helping to accelerate the path to new therapies by providing unprecedented insight into muscle changes over time."

Springbok's involvement in MOVE Peds reinforces its position as an essential partner for acquiring, analyzing, and interpreting MRI data across multi-site studies. By setting a new standard for muscle health analytics, the company is ensuring that the next generation of FSHD clinical trials can benefit from faster and more comprehensive data acquisition, enhanced analytic precision, and novel data mining strategies to optimize our ability to follow and treat FSHD.


About Springbok Analytics:
Springbok Analytics is a leading muscle health analytics company dedicated to advancing health and performance outcomes through innovative, AI-driven solutions that deliver a clearer, more comprehensive view of muscle health.

Built on more than 15 years of research and scientific validation, Springbok's FDA-cleared technology transforms MRI data into personalized, 3D visualizations of muscle health. These detailed analyses provide precise metrics, including individual muscle volume and composition, fat infiltration, asymmetries, scar tissue, edema, and tendon morphology. By offering a more accurate and complete understanding of musculoskeletal health, Springbok enhances diagnostic accuracy, treatment monitoring, research capabilities, and performance optimization.

Back to HCB News

Products and Clearances Homepage